Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Triple Negative Breast Neoplasms × Gemcitabine × Clear all

Phase

Status

Completed 19 Active not recruiting 10 Unknown 6 Terminated 4 Recruiting 3 Withdrawn 1 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 21 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 5 Lung Neoplasms 4 Cholangiocarcinoma 4 Sarcoma 3 Recurrence 3 Neoplasm Metastasis 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma 3 Histiocytoma, Malignant Fibrous 3 Dermatofibrosarcoma 3 Carcinoma, Hepatocellular 3 Bone Neoplasms 3 Biliary Tract Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma, Synovial 2 Rhabdomyosarcoma 2 Neoplasms, Unknown Primary 2 Lymphoma, T-Cell 2 Lymphoma, B-Cell 2 Liposarcoma 2 Leiomyosarcoma 2 Hodgkin Disease 2 Hemangiosarcoma 2 Gallbladder Neoplasms 2 Breast Neoplasms 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Paclitaxel 8 pembrolizumab 7 Doxorubicin 5 Cyclophosphamide 4 Carboplatin 4 130-nm albumin-bound paclitaxel 4 durvalumab 3 olaparib 2 glembatumumab vedotin 2 Radiotherapy 2 Albumin-Bound Paclitaxel 2 yeast-CEA vaccine 1 trifluridine tipiracil drug combination 1 tremelimumab 1 trastuzumab duocarmazine 1 tislelizumab 1 taxane 1 talazoparib 1 sacituzumab govitecan 1 sabizabulin 1 parsaclisib 1 mirvetuximab soravtansine 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 brigimadlin 1 bavituximab 1 avelumab 1 atezolizumab 1 X-Rays 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05809895 2023-07-24

AdvanTIG-211

Novartis

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡